BACKGROUND: Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS. METHODS: The authors studied a cohort of 253 patients with hypocellular MDS diagnosed at The University of Texas MD Anderson Cancer Center between 1993 and 2007 and a cohort of 1725 patients with hyper-/normocellular MDS diagnosed during the same time period. RESULTS: Patients with hypocellular MDS presented more frequently with thrombocytopenia (P < .019), neutropenia (P < .001), low serum β-2 microglobulin (P < .001), increased transfusion dependency (P < .001), and intermediate-2/high-risk disease (57% vs 42%, P = .02) compared with patients with hyper-/normocellular MDS. However, no difference in overall survival was observed between the 2 groups (P = .28). Multivariate analysis identified poor performance status (Eastern Cooperative Oncology Group ≥2), low hemoglobin (<10 g/dL), unfavorable cytogenetics (-7/7q or complex), increased bone marrow blasts (≥5%), and high serum lactate dehydrogenase (>600 IU/L) as adverse independent factors for survival. CONCLUSIONS: A new prognostic model based on these factors was built that segregated patients into 3 distinct risk categories independent of International Prognostic Scoring System (IPSS) score. This model is independent from the IPSS, further refines IPSS-based prognostication, and may be used to develop of risk-adapted therapeutic approaches for patients with hypocellular MDS.
BACKGROUND: Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS. METHODS: The authors studied a cohort of 253 patients with hypocellular MDS diagnosed at The University of Texas MD Anderson Cancer Center between 1993 and 2007 and a cohort of 1725 patients with hyper-/normocellular MDS diagnosed during the same time period. RESULTS:Patients with hypocellular MDS presented more frequently with thrombocytopenia (P < .019), neutropenia (P < .001), low serum β-2 microglobulin (P < .001), increased transfusion dependency (P < .001), and intermediate-2/high-risk disease (57% vs 42%, P = .02) compared with patients with hyper-/normocellular MDS. However, no difference in overall survival was observed between the 2 groups (P = .28). Multivariate analysis identified poor performance status (Eastern Cooperative Oncology Group ≥2), low hemoglobin (<10 g/dL), unfavorable cytogenetics (-7/7q or complex), increased bone marrow blasts (≥5%), and high serum lactate dehydrogenase (>600 IU/L) as adverse independent factors for survival. CONCLUSIONS: A new prognostic model based on these factors was built that segregated patients into 3 distinct risk categories independent of International Prognostic Scoring System (IPSS) score. This model is independent from the IPSS, further refines IPSS-based prognostication, and may be used to develop of risk-adapted therapeutic approaches for patients with hypocellular MDS.
Authors: Vikas Gupta; Carol Brooker; Jennifer A Tooze; Qi-Long Yi; Deborah Sage; David Turner; Pamela Kangasabapathy; Judith C W Marsh Journal: Br J Haematol Date: 2006-07 Impact factor: 6.998
Authors: D E Dunn; P Tanawattanacharoen; P Boccuni; S Nagakura; S W Green; M R Kirby; M S Kumar; S Rosenfeld; N S Young Journal: Ann Intern Med Date: 1999-09-21 Impact factor: 25.391
Authors: Marcin W Wlodarski; Lukasz P Gondek; Zachary P Nearman; Magdalena Plasilova; Matt Kalaycio; Eric D Hsi; Jaroslaw P Maciejewski Journal: Blood Date: 2006-04-13 Impact factor: 22.113
Authors: Gang Yue; Suyang Hao; Oluwole Fadare; Stephen Baker; Olga Pozdnyakova; Naomi Galili; Bruce A Woda; Azra Raza; Sa A Wang Journal: Leuk Res Date: 2007-09-20 Impact factor: 3.156
Authors: Sergej Konoplev; L Jeffrey Medeiros; Patrick A Lennon; Sapana Prajapati; Anuradha Kanungo; Pei Lin Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola Journal: J Clin Oncol Date: 2007-08-10 Impact factor: 44.544
Authors: Z Y Lim; S Killick; U Germing; J Cavenagh; D Culligan; A Bacigalupo; J Marsh; G J Mufti Journal: Leukemia Date: 2007-05-17 Impact factor: 11.528
Authors: Theo de Witte; David Bowen; Marie Robin; Luca Malcovati; Dietger Niederwieser; Ibrahim Yakoub-Agha; Ghulam J Mufti; Pierre Fenaux; Guillermo Sanz; Rodrigo Martino; Emilio Paolo Alessandrino; Francesco Onida; Argiris Symeonidis; Jakob Passweg; Guido Kobbe; Arnold Ganser; Uwe Platzbecker; Jürgen Finke; Michel van Gelder; Arjan A van de Loosdrecht; Per Ljungman; Reinhard Stauder; Liisa Volin; H Joachim Deeg; Corey Cutler; Wael Saber; Richard Champlin; Sergio Giralt; Claudio Anasetti; Nicolaus Kröger Journal: Blood Date: 2017-01-17 Impact factor: 22.113
Authors: Daiane Corrêa de Souza; Cecília de Souza Fernandez; Adriana Camargo; Alexandre Gustavo Apa; Elaine Sobral da Costa; Luis Fernando Bouzas; Eliana Abdelhay; Teresa de Souza Fernandez Journal: Biomed Res Int Date: 2014-08-11 Impact factor: 3.411
Authors: Judith Strapatsas; Elena Calina Barbulescu; Michael Lauseker; Jennifer Kaivers; Barbara Hildebrandt; Kathrin Nachtkamp; Corinna Strupp; Martina Rudelius; Rainer Haas; Ulrich Germing Journal: Ann Hematol Date: 2021-07-29 Impact factor: 3.673